Cat. No.: HY-15036

Diclofenac

24 Cited Publications

Customer Review

Based on 24 publication(s) in Google Scholar

Diclofenac is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC₅₀s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells, and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively. Diclofenac induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade.

For research use only. We do not sell to patients.

Purity: 99.92%
CAS No.: 15307-86-5
Formula: C₁₄H₁₁Cl₂NO₂
Molecular Weight:296.15

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Diclofenac Chemical Structure

CAS No.: 15307-86-5

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (24)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Diclofenac is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC₅₀s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells^[1], and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively^[2]. Diclofenac induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade^[3].

IC₅₀ & Target^[1]^[2]

Human COX-2

1.3 nM (IC₅₀, in CHO cells)

Human COX-1

4 nM (IC₅₀, in CHO cells)

Ovine COX-2

0.84 μM (IC₅₀)

Ovine COX-1

5.1 μM (IC₅₀)

All COX Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	IC₅₀	4 μM Compound: Diclofenac	TP_TRANSPORTER: inhibition of Adefovir uptake in OAT1-expressing CHO cells TP_TRANSPORTER: inhibition of Adefovir uptake in OAT1-expressing CHO cells	[PMID: 10991954]
Erythrocyte	IC₅₀	0.942 μM Compound: Diclofenac	Anti-inflammatory activity in human RBC assessed as membrane stabilization Anti-inflammatory activity in human RBC assessed as membrane stabilization	[PMID: 28818769]
HEK293	EC₅₀	56 μM Compound: DCF	Agonist activity at human TRPA1 expressed in HEK293 cells assessed as increase in calcium influx by Fluo-4-AM dye based fluorescence assay Agonist activity at human TRPA1 expressed in HEK293 cells assessed as increase in calcium influx by Fluo-4-AM dye based fluorescence assay	[PMID: 30878828]
HEK293	IC₅₀	>500 μM Compound: diclofenac	Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	[PMID: 23241029]
HUVEC	IC₅₀	0.75 mM Compound: Diclofenac	Antiinflammatory activity in HUVEC assessed as inhibition of LPS-induced ICAM1 expression by cell-ELISA Antiinflammatory activity in HUVEC assessed as inhibition of LPS-induced ICAM1 expression by cell-ELISA	10.1039/C0MD00262C
L1.2	IC₅₀	>10 μM Compound: 1	Inhibition of CXCR1 Lys99Ala mutant transfected in mouse L1.2 cells assessed as inhibition of CXCL8-induced cell migration pretreated for 15 mins measured after 4 hrs Inhibition of CXCR1 Lys99Ala mutant transfected in mouse L1.2 cells assessed as inhibition of CXCL8-induced cell migration pretreated for 15 mins measured after 4 hrs	[PMID: 19560921]
L1.2	IC₅₀	12 nM Compound: 1	Inhibition of wild type CXCR1 transfected in mouse L1.2 cells assessed as inhibition of CXCL8-induced cell migration pretreated for 15 mins measured after 4 hrs Inhibition of wild type CXCR1 transfected in mouse L1.2 cells assessed as inhibition of CXCL8-induced cell migration pretreated for 15 mins measured after 4 hrs	[PMID: 19560921]
RAW264.7	IC₅₀	10.18 μM Compound: Diclofenac	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-6 production preincubated for 2 hrs followed by LPS stimulation and measured after 20 hrs by ELISA Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-6 production preincubated for 2 hrs followed by LPS stimulation and measured after 20 hrs by ELISA	[PMID: 37611534]
RAW264.7	IC₅₀	10.45 μM Compound: Diclofenac	Antiinflammatory activity in LPS-activated mouse RAW264.7 cells assessed as inhibition of TNF-alpha production preincubated for 2 hrs followed by LPS addition measured after 20 hrs by ELISA method Antiinflammatory activity in LPS-activated mouse RAW264.7 cells assessed as inhibition of TNF-alpha production preincubated for 2 hrs followed by LPS addition measured after 20 hrs by ELISA method	[PMID: 37182334]
RAW264.7	IC₅₀	19.59 μM Compound: Diclofenac	Antiinflammatory activity in LPS-activated mouse RAW264.7 cells assessed as inhibition of IL-6 production preincubated for 2 hrs followed by LPS addition measured after 20 hrs by ELISA method Antiinflammatory activity in LPS-activated mouse RAW264.7 cells assessed as inhibition of IL-6 production preincubated for 2 hrs followed by LPS addition measured after 20 hrs by ELISA method	[PMID: 37182334]
RAW264.7	IC₅₀	21.34 μM Compound: Diclofenac	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha production preincubated for 2 hrs followed by LPS stimulation and measured after 20 hrs by ELISA Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha production preincubated for 2 hrs followed by LPS stimulation and measured after 20 hrs by ELISA	[PMID: 37611534]
RAW264.7	IC₅₀	25.34 μM Compound: Diclofenac	Antiinflammatory activity in LPS-activated mouse RAW264.7 cells assessed as inhibition of NO production preincubated for 2 hrs followed by LPS addition measured after 20 hrs by DAF-FM staining based assay Antiinflammatory activity in LPS-activated mouse RAW264.7 cells assessed as inhibition of NO production preincubated for 2 hrs followed by LPS addition measured after 20 hrs by DAF-FM staining based assay	[PMID: 37182334]
RAW264.7	IC₅₀	26.26 μM Compound: Diclofenac	Antiinflammatory activity in LPS-activated mouse RAW264.7 cells assessed as inhibition of ROS production by DCFH-DA staining based assay Antiinflammatory activity in LPS-activated mouse RAW264.7 cells assessed as inhibition of ROS production by DCFH-DA staining based assay	[PMID: 37182334]
RAW264.7	IC₅₀	50.08 μM Compound: Diclofenac	Antioxidant activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced ROS production preincubated with compound for 2 hrs followed by LPS stimulation and measured after 20 hrs by DCFH-DA probe based fluorescence analysis Antioxidant activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced ROS production preincubated with compound for 2 hrs followed by LPS stimulation and measured after 20 hrs by DCFH-DA probe based fluorescence analysis	[PMID: 37611534]
RAW264.7	IC₅₀	54.66 μM Compound: Diclofenac	Antioxidant activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated with compound for 2 hrs followed by LPS stimulation and measured after 20 hrs by fluorescence microscopic analysis Antioxidant activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated with compound for 2 hrs followed by LPS stimulation and measured after 20 hrs by fluorescence microscopic analysis	[PMID: 37611534]
Sf21	IC₅₀	23.62 μM Compound: Diclofenac	Inhibition of human recombinant COX2 expressed in baculovirus infected SF21 cell Inhibition of human recombinant COX2 expressed in baculovirus infected SF21 cell	[PMID: 20974503]
Sf9	IC₅₀	0.03 μM Compound: diclofenac	Inhibition of human COX1 expressed in sf9 cells Inhibition of human COX1 expressed in sf9 cells	[PMID: 16252917]
Sf9	IC₅₀	0.07 μM Compound: diclofenac	Inhibition of human COX2 expressed in sf9 cells Inhibition of human COX2 expressed in sf9 cells	[PMID: 16252917]
THP-1	IC₅₀	143 μM Compound: Diclofenac	Inhibition of PMA-induced human THP1 monocytes differentiation in to macrophages assessed as macrophage metabolic activity preincubated for 6 hrs before PMA stimulation Inhibition of PMA-induced human THP1 monocytes differentiation in to macrophages assessed as macrophage metabolic activity preincubated for 6 hrs before PMA stimulation	[PMID: 30818268]
THP-1	IC₅₀	4.86 μM Compound: Diclofenac	Inhibition of PMA-induced human THP1 monocytes differentiation in to macrophages preincubated for 6 hrs followed by PMA stimulation by phase contrast microscopic method Inhibition of PMA-induced human THP1 monocytes differentiation in to macrophages preincubated for 6 hrs followed by PMA stimulation by phase contrast microscopic method	[PMID: 29289887]
Ventricular myocyte	IC₅₀	12.89 μM Compound: Diclofenac	Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes	[PMID: 22761000]

In Vitro

Diclofenac effectively blocks COX-1 mediated prostanoid production from U937 cell microsomes, with an IC₅₀ of 7±3 nM^[1].
Diclofenac (1-60 μM; 1 day) induces neural stem cells (NSCs)death in a concentration-dependent manner^[3].
Diclofenac (10-60 μM; 6 hours) increases the expression of cleaved (activated) caspase-3^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[3]

Cell Line:

Neural stem cells (NSCs)
Concentration:

1, 3, 10, 30, 60 μM
Incubation Time:

1 day
Result:

Induction of cell death was concentration-dependent and the effect was not saturated at a concentration of up to 60 μM.

Western Blot Analysis^[3]

Cell Line:

Neural stem cells (NSCs)
Concentration:

10, 30 or 60 μM
Incubation Time:

6 hours
Result:

The activation of caspase-3 was increased in a concentration-dependent manner.

In Vivo

Diclofenac (3 mg/kg, b.i.d., for 5 days) significantly increases faecal ⁵¹Cr excretion in rats, and such effect is also observed in squirrel monkeys after administrated of 1 mg/kg twice daily for 4 days^[1].
Diclofenac (10 mg/kg; administered via oral route just prior to induction of inflammation) shows in vivo anti-inflammatory activity in Wistar rats^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male Sprague-Dawley rats (150±200 g)^[1]
Dosage:

3 mg/kg
Administration:

Oral administration, b.i.d., for 5 days
Result:

Resulted in a significant increase in faecal ⁵¹Cr excretion.

Animal Model:

Wistar rats (150-175 g) bearing Formalin-induced rat foot paw edema model^[2]
Dosage:

10 mg/kg
Administration:

Administered via oral route just prior to induction of inflammation
Result:

Showed in vivo anti-inflammatory activity (% edema inhibition=29.2, 1 h; 22.2, 3 h; 20, 6 h).

Chemical Information

CAS No. 15307-86-5
Appearance Solid
Molecular Weight 296.15
Formula C₁₄H₁₁Cl₂NO₂
Color White to light yellow
SMILES

O=C(O)CC1=CC=CC=C1NC2=C(Cl)C=CC=C2Cl
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (24)

All Cell Proliferation/Viability AssayFlow CytometryWBCell Imaging/Staining

Sort by:

Journal Impact Factor

Adv Funct Mater

2026 Feb 3.
J Hazard Mater

Microwave-assisted activated carbon from cocoa shell as adsorbent for removal of sodium diclofenac and nimesulide from aqueous effluents. [Abstract]

2015 May 30;289:18-27. PMID: 25702636
Biomater Res

Distinct Roles of Matrigel Enabled the Production of Expandable Hepatoblast and Polarized Hepatocyte Organoids from Human Embryonic Stem Cells under 3-Dimensional Suspension Conditions. [Abstract]

2025 Nov 7:29:0280. PMID: 41209312
Int J Biol Macromol

Reticuline isomerase AKR1B1 with aldo-keto reductase activity and detoxification function from the insect Blaps rhynchopetera. [Abstract]

2026 Mar:352:151224. PMID: 41791543
Chemosphere

Mass-balance-model-based evaluation of sewage treatment plant contribution to residual pharmaceuticals in environmental waters. [Abstract]

2019 Jun:225:378-387. PMID: 30884299
Emerg Contam

2026 Feb 23.
Cell Rep

Spatial proteomics identifies a CRTC-dependent viral signaling pathway that stimulates production of interleukin-11. [Abstract]

2025 Feb 7;44(2):115263. PMID: 39921859
Anal Chem

Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]

2025 Jun 3;97(21):11099-11109. PMID: 40401576
Ecotoxicol Environ Saf

PPARγ-responsive luciferase reporter system for high-throughput screening of chemical toxins with potential pulmonary fibrosis effects. [Abstract]

2025 Nov 15:307:119433. PMID: 41273832
Chem Biol Interact

Regulatory effects of non-steroidal anti-inflammatory drugs on cardiac ion channels Nav1.5 and Kv11.1. [Abstract]

2021 Apr 1:338:109425. PMID: 33617802
Int J Mol Sci

Diclofenac Sensitizes Signet Ring Cell Gastric Carcinoma Cells to Cisplatin by Activating Autophagy and Inhibition of Survival Signal Pathways. [Abstract]

2022 Oct 11;23(20):12066. PMID: 36292923

Diclofenac purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2022 Oct 11;23(20):12066. [Abstract]

KATOIII and KATO/DDP were treated with different concentration of Diclofenac (DCF) (0–1000 µM) for 48 h, and cell viability was assessed.

Diclofenac purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2022 Oct 11;23(20):12066. [Abstract]

The KATO/DDP cells were treated with Cisplatin alone or cisplatin in combination with Diclofenac (DCF) at 10 or 20 µM for 24 h, at 37 °C. The apoptosis cells were detected by using annexin V and PI staining and analyzed by flow cytometer.

Diclofenac purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2022 Oct 11;23(20):12066. [Abstract]

The combination effect of Diclofenac (DCF) (0, 5, 10, 20 μM) and Cisplatin on the expression of cleaved PARP in KATO/DDP cells was examined by Western blot analysis.

Diclofenac purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2022 Oct 11;23(20):12066. [Abstract]

The formation of autophagic vacuoles in KATO/DDP cells increased from 27% to 39% and 45% in cotreatments involving cisplatin and Diclofenac (DCF) at 10 and 20 μM, respectively, when compared with treatment of cisplatin alone.
J Phys Chem Solids

2017 October;109:117-123.
Cell Rep Methods

RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]

2023 Oct 23;3(10):100599. PMID: 37797618
Pharm Res

Effect of Salt Form on Gelation and Drug Delivery Properties of Diclofenac-Loaded Poloxamer Gels for Delivery to Impaired Skin. [Abstract]

2022 Oct;39(10):2515-2527. PMID: 36002613
ACS Infect Dis

Diclofenac Sodium Restores the Sensitivity of Colistin-Resistant Gram-Negative Bacteria to Colistin. [Abstract]

2024 Aug 9;10(8):2860-2869. PMID: 39073350
Biotechnol Bioeng

An integrated biomimetic array chip for establishment of collagen-based 3D primary human hepatocyte model for prediction of clinical drug-induced liver injury. [Abstract]

2021 Dec;118(12):4687-4698. PMID: 34478150
J Pharm Biomed Anal

A validated UHPLC-MS/MS method for simultaneous determination of lumiracoxib and its hydroxylation and acyl glucuronidation metabolites in rat plasma: Application to a pharmacokinetic study. [Abstract]

2021 Jul 15:201:114105. PMID: 33991809
Phys Chem Chem Phys

Adsorption of sodium diclofenac on graphene: a combined experimental and theoretical study. [Abstract]

2016 Jan 21;18(3):1526-36. PMID: 26671178
Toxicol Mech Methods

Evaluation of 3D re-cellularized tissue engineering: a drug-induced hepatotoxicity model for hepatoprotectant research. [Abstract]

2019 Nov;29(9):654-664. PMID: 31345115
Arch Microbiol

Diclofenac sodium effectively inhibits the biofilm formation of Staphylococcus epidermidis. [Abstract]

2024 Jun 7;206(7):289. PMID: 38847838
Eur J Drug Metab Pharmacokinet

Evaluation of an Ussing Chamber System Equipped with Rat Intestinal Tissues to Predict Intestinal Absorption and Metabolism in Humans. [Abstract]

2022 Sep;47(5):639-652. PMID: 35733077
Thai Journal of Pharmaceutical Sciences

2025 Dec.
bioRxiv

2024 Apr 7.
Federal University of Rio Grande do Sul

2017 Nov.

Solvent & Solubility

In Vitro:

DMSO : 125 mg/mL (422.08 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.3767 mL

16.8833 mL

33.7667 mL

5 mM

0.6753 mL

3.3767 mL

6.7533 mL

10 mM

0.3377 mL

1.6883 mL

3.3767 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (7.02 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (7.02 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (788 KB)
- English - EN (788 KB)
- Français - FR (788 KB)
- Deutsch - DE (788 KB)
- Norwegian - NO (788 KB)
- Español - ES (788 KB)
- Swedish - SV (788 KB)
- Italian - IT (788 KB)
- Korean - KR (788 KB)
- Portuguese - PT (788 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Riendeau D, et al. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol. 1997 May;121(1):105-17. [Content Brief]

[2]. Labib MB, et al. Design, synthesis of novel isoindoline hybrids as COX-2 inhibitors: Anti-inflammatory, analgesic activities and docking study. Bioorg Chem. 2018 Oct;80:70-80. [Content Brief]

[3]. Chiho Kudo, et al. Diclofenac Inhibits Proliferation and Differentiation of Neural Stem Cells. Biochem Pharmacol. 2003 Jul 15;66(2):289-95. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.3767 mL	16.8833 mL	33.7667 mL	84.4167 mL
	5 mM	0.6753 mL	3.3767 mL	6.7533 mL	16.8833 mL
	10 mM	0.3377 mL	1.6883 mL	3.3767 mL	8.4417 mL
	15 mM	0.2251 mL	1.1256 mL	2.2511 mL	5.6278 mL
	20 mM	0.1688 mL	0.8442 mL	1.6883 mL	4.2208 mL
	25 mM	0.1351 mL	0.6753 mL	1.3507 mL	3.3767 mL
	30 mM	0.1126 mL	0.5628 mL	1.1256 mL	2.8139 mL
	40 mM	0.0844 mL	0.4221 mL	0.8442 mL	2.1104 mL
	50 mM	0.0675 mL	0.3377 mL	0.6753 mL	1.6883 mL
	60 mM	0.0563 mL	0.2814 mL	0.5628 mL	1.4069 mL
	80 mM	0.0422 mL	0.2110 mL	0.4221 mL	1.0552 mL
	100 mM	0.0338 mL	0.1688 mL	0.3377 mL	0.8442 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Diclofenac

Apoptosis Compound Library

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

CNS-Penetrant Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

NMPA-Approved Drug Library

Pyroptosis Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Pancreatic Cancer Compound Library

Mechanoreceptors Compound Library

Rare Diseases Drug Library

Anti-Colorectal Cancer Compound Library

Pediatric Drug Library

Antidepressant Compound Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Off-patent Drug Library

Mitochondrial Toxicity Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Cardiotoxic Compound Library

RNA Binding Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Diclofenac

All COX Isoforms

Biological Activity

Chemical Information

Publications (24)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Diclofenac Related Classifications

HY-15036 Related Classifications